A phase I dose escalation (DE) study of ERK inhibitor, LY3214996, in advanced (adv) cancer (CA) patients (pts).

出版年份 2019 全文链接

标题

作者

关键词

出版物

Volume 37, Issue 15_suppl, Pages 3001-3001

出版商

American Society of Clinical Oncology (ASCO)

发表日期

2019-05-27

DOI

10.1200/jco.2019.37.15_suppl.3001

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now